In Brief: Zila
This article was originally published in The Tan Sheet
Executive Summary
Zila: Signs definitive agreement to acquire Ester-C maker Oxycal Labs, the Phoenix, Ariz.-based dental healthcare product company announces. Oxycal, a privately held, Prescott, Ariz.-based maker of the patented form of vitamin C, manufactures Ester-C by combining vitamin C with either calcium, magnesium, zinc, sodium or potassium to produce a compound that is less acidic and contains vitamin C metabolites. Oxycal distributes the ingredient in bulk form to over 100 supplement manufacturers. Zila, which markets the Zilactin brand of oral analgesics as its only OTC offering, says "Oxycal is highly profitable," noting the firm "holds important technology patents which...have potential applications in the pharmaceutical industry." Completion of the agreement must be ratified by Oxycal shareholders, who are scheduled to vote around Nov. 10. Terms were not disclosed...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning